Pages that link to "Q28287860"

The following pages link to Intravenous anakinra can achieve experimentally effective concentrations in the central nervous system within a therapeutic time window: results of a dose-ranging study (Q28287860):

Displaying 45 items.

• Central and haematopoietic interleukin-1 both contribute to ischaemic brain injury in mice (Q28287669) (← links)
• Neuroinflammation and cerebrovascular disease in old age: a translational medicine perspective (Q28393202) (← links)
• Interleukin-1 Antagonist Anakinra in Amyotrophic Lateral Sclerosis--A Pilot Study (Q28550089) (← links)
• The relationship between interleukin-1 receptor antagonist and cognitive function in older adults with bipolar disorder (Q33578766) (← links)
• Recombinant human interleukin-1 receptor antagonist in severe traumatic brain injury: a phase II randomized control trial. (Q33581165) (← links)
• Protease-activated receptor-1 activation by granzyme B causes neurotoxicity that is augmented by interleukin-1β (Q33846630) (← links)
• The meteorology of cytokine storms, and the clinical usefulness of this knowledge (Q33867213) (← links)
• Translational pharmacokinetics: challenges of an emerging approach to drug development in stroke. (Q33882182) (← links)
• Interleukin-1 receptor blockade in perinatal brain injury (Q34297349) (← links)
• The dual role of the neuroinflammatory response after ischemic stroke: modulatory effects of hypothermia (Q34335614) (← links)
• Cerebrospinal fluid markers of neuroinflammation in delirium: a role for interleukin-1β in delirium after hip fracture (Q34760173) (← links)
• Role of the IL-1 receptor antagonist in ethanol-induced regulation of GABAergic transmission in the central amygdala (Q35509638) (← links)
• LPS preconditioning redirects TLR signaling following stroke: TRIF-IRF3 plays a seminal role in mediating tolerance to ischemic injury. (Q35555026) (← links)
• Acute anti‐inflammatory approaches to ischemic stroke (Q36003814) (← links)
• Transient increase of interleukin-1β after prolonged febrile seizures promotes adult epileptogenesis through long-lasting upregulating endocannabinoid signaling. (Q36606116) (← links)
• Cell therapy centered on IL-1Ra is neuroprotective in experimental stroke (Q36809420) (← links)
• Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases (Q36816872) (← links)
• Fasting induces an anti-inflammatory effect on the neuroimmune system which a high-fat diet prevents (Q36963797) (← links)
• The effect of intravenous interleukin-1 receptor antagonist on inflammatory mediators in cerebrospinal fluid after subarachnoid haemorrhage: a phase II randomised controlled trial. (Q37480217) (← links)
• Interleukin-1 as a mediator of fatigue in disease: a narrative review (Q37597282) (← links)
• Proteomic analysis of saliva in HIV-positive heroin addicts reveals proteins correlated with cognition (Q37694708) (← links)
• Regulation of interleukin-1 in acute brain injury (Q37905329) (← links)
• Interleukin-1 and stroke: biomarker, harbinger of damage, and therapeutic target (Q37959134) (← links)
• Inflammatory cytokines in experimental and human stroke. (Q38022155) (← links)
• Central nervous system circuits modified in heart failure: pathophysiology and therapeutic implications. (Q38191484) (← links)
• Phase II anti-inflammatory and immune-modulating drugs for acute ischaemic stroke (Q38366399) (← links)
• Interleukin-1 as a pharmacological target in acute brain injury (Q38533781) (← links)
• IL-1α Gene Deletion Protects Oligodendrocytes after Spinal Cord Injury through Upregulation of the Survival Factor Tox3. (Q38847946) (← links)
• Therapeutic Strategies Under Development Targeting Inflammatory Mechanisms in Amyotrophic Lateral Sclerosis (Q39271545) (← links)
• Study design and population pharmacokinetic analysis of a phase II dose-ranging study of interleukin-1 receptor antagonist (Q40420576) (← links)
• Interleukin-1 receptor antagonist is beneficial after subarachnoid haemorrhage in rat by blocking haem-driven inflammatory pathology (Q41614701) (← links)
• Requirement for interleukin-1 to drive brain inflammation reveals tissue-specific mechanisms of innate immunity. (Q41678554) (← links)
• Recent pharmacological advances in the management of gout. (Q47919692) (← links)
• Colorectal distention induces acute and delayed visceral hypersensitivity: role of peripheral corticotropin-releasing factor and interleukin-1 in rats. (Q48263316) (← links)
• In enterovirus 71 encephalitis with cardio-respiratory compromise, elevated interleukin 1β, interleukin 1 receptor antagonist, and granulocyte colony-stimulating factor levels are markers of poor prognosis (Q48429651) (← links)
• Combined Blockade of Interleukin-1α and -1β Signaling Protects Mice from Cognitive Dysfunction after Traumatic Brain Injury. (Q55264993) (← links)
• Anakinra Therapy for Non-cancer Inflammatory Diseases (Q59136398) (← links)
• Haemoglobin scavenging in intracranial bleeding: biology and clinical implications (Q89170893) (← links)
• Modulation of Post-Traumatic Immune Response Using the IL-1 Receptor Antagonist Anakinra for Improved Visual Outcomes (Q89708348) (← links)
• The IL-1 Antagonist Anakinra Attenuates Glioblastoma Aggressiveness by Dampening Tumor-Associated Inflammation (Q89761200) (← links)
• Blood-Related Toxicity after Traumatic Brain Injury: Potential Targets for Neuroprotection (Q90737477) (← links)
• Post-stroke inflammation-target or tool for therapy? (Q93358519) (← links)
• Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome (Q94565447) (← links)
• Current Therapeutic Options for the Main Monogenic Autoinflammatory Diseases and PFAPA Syndrome: Evidence-Based Approach and Proposal of a Practical Guide (Q97521410) (← links)
• The Lazarus effect of very high-dose intravenous anakinra in severe non-familial CNS-HLH (Q100753213) (← links)